Verge Genomics

About

Verge Genomics has developed CONVERGE®, an AI-powered drug discovery platform utilizing a large, proprietary human multi-omics database to identify and validate drug candidates for neurodegenerative diseases. Their platform leverages machine learning to analyze human tissue data, enabling the rapid identification of novel targets and accelerating drug development – most notably, their lead compound VRG50635, a PIKfyve inhibitor for ALS, entered clinical trials just four years after initial research. Currently focused on ALS, Parkinson’s Disease, and Frontotemporal Dementia, Verge aims to deliver breakthrough treatments for diseases with limited or no effective therapies.

Focus Areas

Technology Focus

Key People 1

• A Alice Zhang